MediWound Ltd. (Nasdaq: MDWD), an Israeli fully-integrated biopharmaceutical company, has signed an agreement with Holy Stone Healthcare Co., Ltd. (4194.TW) on October 16, 2017, granting Holy Stone Healthcare the exclusive distribution rights of NexoBrid® in Taiwan.
MediWound is specializing, on developing and manufacturing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications.
MediWound’s drug, NexoBrid®, was approved by the European Medicines Agency (EMA) and the Israeli and Argentinian Ministries of Health and is commercially available in Europe, and also in Israel, and Argentina. This innovative drug is indicated for removal of eschar (debridement) in adults with deep partial- and full-thickness thermal burns. The debridement is a critical first step in the successful healing of severe burns as well as chronic and other hard-to-heal wounds. Clinical trials of NexoBrid® have shown that implementation of NexoBrid® into burn care significantly minimized the need for surgical debridement, and achieved better patients’ outcomes(1)(2), including less traumatic/surgeries, spare viable tissue, rapid debridement, less procedural pain and blood loss, and reduced skin area for grafting. NexoBrid® also reduced the burdens of healthcare resources spending, including less loading/use of surgeons, facilities, and anesthesia, therefore improved overall complexity and effectiveness of burn care.
Holy Stone Healthcare is now preparing for acquiring the marketing authorization of NexoBrid® in Taiwan.
1. Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multicenter RCT. Burns 2014; 40: 466–74.
2. L. Rosenberg, Y. Shoham, Y. Krieger, G. Rubin, F. Sander, J. Koller, K. David, D. Egosi, R. Ahuja, and A.J. Singer. Minimally invasive burn care: a review of seven clinical studies of rapid and selective debridement using a bromelain-based debriding enzyme (Nexobrid®). Ann Burns Fire Disasters 2015; 28: 264–274.